Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Immutep Limited, seeking damages for investors who purchased the company's securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that Immutep's executives made materially false and misleading statements throughout the class period, failing to disclose the true status of the TACTI-004 clinical trial, which may have led to investor misjudgment regarding the company's prospects and impacted its stock price.
- Legal Consequences for Investors: Investors must apply to be lead plaintiffs by July 6, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal proceedings in protecting investor rights and interests.
- Law Firm's Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions of dollars for investors, emphasizing its expertise in securities fraud class actions and its commitment to providing legal support for affected investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.361
Low
12.00
Averages
12.00
High
12.00
Current: 0.361
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Immutep Limited, seeking damages for investors who purchased the company's securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that Immutep's executives made materially false and misleading statements throughout the class period, failing to disclose the true status of the TACTI-004 clinical trial, which may have led to investor misjudgment regarding the company's prospects and impacted its stock price.
- Legal Consequences for Investors: Investors must apply to be lead plaintiffs by July 6, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal proceedings in protecting investor rights and interests.
- Law Firm's Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions of dollars for investors, emphasizing its expertise in securities fraud class actions and its commitment to providing legal support for affected investors.
See More
Immutep Limited Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited, alleging that the company misled investors regarding its drug candidate during the period from March 24, 2025, to March 12, 2026, focusing on its cancer immunotherapy efforts.
- Clinical Trial Issues: The complaint claims that Immutep concealed internal data from the TACTI-004 clinical trial, which increased the risk that the study would fail to meet its primary efficacy and safety endpoints, leaving investors unaware of these significant risks.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the TACTI-004 trial was recommended for discontinuation due to futility by the Independent Data Monitoring Committee, Immutep's ADR price plummeted from $2.76 to $0.48, representing an approximate 83% decline.
- Investor Actions: Shareholders interested in serving as lead plaintiffs in the class action must submit their papers by July 6, 2026, allowing them to represent other investors in the litigation without needing to participate actively in the case to be eligible for recovery.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Immutep is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from March 24, 2025, to March 12, 2026, with a deadline for investor contact set for July 6, 2026.
- False Statements Exposed: The complaint reveals that Immutep concealed results from its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, severely undermining investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to seek compensation, demonstrating a commitment to protecting investor rights.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, reflecting strong investor response to potential fraud allegations against the company.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of its TACTI-004 trial, particularly by relying on previous positive results to make misleading claims, severely undermining investor confidence in the company's future.
- Increased Risk Warning: The lawsuit highlights that executives at Immutep were aware of the significantly increased risk of the TACTI-004 trial failing to meet primary efficacy and safety endpoints but failed to disclose this information to investors, potentially leading to substantial losses for them.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by July 6, 2026, to share in any potential recovery from the lawsuit, indicating that legal avenues are available for investors to seek redress.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiff by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency in clinical trials.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Immutep Limited Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the progress of its drug candidate TACTI-004 between March 24, 2025, and March 12, 2026.
- Clinical Trial Issues: The complaint states that Immutep falsely claimed “strong operational progress” in the TACTI-004 trial while concealing internal data indicating a significant risk of failing to meet primary efficacy and safety endpoints.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial, Immutep's ADR price plummeted from $2.76 to $0.48, an 83% decline, severely impacting investor confidence.
- Shareholder Action Advice: Affected shareholders are encouraged to submit their papers by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the importance of corporate governance and shareholder rights.
See More
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Immutep Limited, seeking damages for investors who purchased the company's securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that Immutep's executives made materially false and misleading statements throughout the class period, failing to disclose the true status of the TACTI-004 clinical trial, which may have led to investor misjudgment regarding the company's prospects and impacted its stock price.
- Legal Consequences for Investors: Investors must apply to be lead plaintiffs by July 6, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal proceedings in protecting investor rights and interests.
- Law Firm's Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions of dollars for investors, emphasizing its expertise in securities fraud class actions and its commitment to providing legal support for affected investors.
See More
Immutep Limited Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited, alleging that the company misled investors regarding its drug candidate during the period from March 24, 2025, to March 12, 2026, focusing on its cancer immunotherapy efforts.
- Clinical Trial Issues: The complaint claims that Immutep concealed internal data from the TACTI-004 clinical trial, which increased the risk that the study would fail to meet its primary efficacy and safety endpoints, leaving investors unaware of these significant risks.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the TACTI-004 trial was recommended for discontinuation due to futility by the Independent Data Monitoring Committee, Immutep's ADR price plummeted from $2.76 to $0.48, representing an approximate 83% decline.
- Investor Actions: Shareholders interested in serving as lead plaintiffs in the class action must submit their papers by July 6, 2026, allowing them to represent other investors in the litigation without needing to participate actively in the case to be eligible for recovery.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Immutep is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from March 24, 2025, to March 12, 2026, with a deadline for investor contact set for July 6, 2026.
- False Statements Exposed: The complaint reveals that Immutep concealed results from its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, severely undermining investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to seek compensation, demonstrating a commitment to protecting investor rights.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, reflecting strong investor response to potential fraud allegations against the company.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of its TACTI-004 trial, particularly by relying on previous positive results to make misleading claims, severely undermining investor confidence in the company's future.
- Increased Risk Warning: The lawsuit highlights that executives at Immutep were aware of the significantly increased risk of the TACTI-004 trial failing to meet primary efficacy and safety endpoints but failed to disclose this information to investors, potentially leading to substantial losses for them.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by July 6, 2026, to share in any potential recovery from the lawsuit, indicating that legal avenues are available for investors to seek redress.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiff by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency in clinical trials.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Immutep Limited Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the progress of its drug candidate TACTI-004 between March 24, 2025, and March 12, 2026.
- Clinical Trial Issues: The complaint states that Immutep falsely claimed “strong operational progress” in the TACTI-004 trial while concealing internal data indicating a significant risk of failing to meet primary efficacy and safety endpoints.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial, Immutep's ADR price plummeted from $2.76 to $0.48, an 83% decline, severely impacting investor confidence.
- Shareholder Action Advice: Affected shareholders are encouraged to submit their papers by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the importance of corporate governance and shareholder rights.
See More
